{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:24:41Z","timestamp":1791901481242,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous booster in adults previously vaccinated with CoronaVac in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04892459\">NCT04892459<\/jats:ext-link>\n                    ). Adults who had received two doses of CoronaVac in the past 3\u20136 months were vaccinated with Convidecia (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200996) or CoronaVac (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009102). Adults who had received one dose of CoronaVac in the past 1\u20133 months were also vaccinated with Convidecia (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200951) or CoronaVac (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200950). The co-primary endpoints were the occurrence of adverse reactions within 28\u2009d after vaccination and geometric mean titers (GMTs) of neutralizing antibodies against live wild-type SARS-CoV-2 virus at 14\u2009d after booster vaccination. Adverse reactions after vaccination were significantly more frequent in Convidecia recipients but were generally mild to moderate in all treatment groups. Heterologous boosting with Convidecia elicited significantly increased GMTs of neutralizing antibody against SARS-CoV-2 than homologous boosting with CoronaVac in participants who had previously received one or two doses of CoronaVac. These data suggest that heterologous boosting with Convidecia following initial vaccination with CoronaVac is safe and more immunogenic than homologous boosting.\n                  <\/jats:p>","DOI":"10.1038\/s41591-021-01677-z","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T06:03:15Z","timestamp":1643263395000},"page":"401-409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial"],"prefix":"10.1038","volume":"28","author":[{"given":"Jingxin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7366-8974","authenticated-orcid":false,"given":"Lihua","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8083-247X","authenticated-orcid":false,"given":"Shipo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhou","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunbiao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lairun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5805-2469","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1644-0006","authenticated-orcid":false,"given":"Fengcai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"1677_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","volume":"20","author":"E Dong","year":"2020","unstructured":"Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infect. Dis. 20, 533\u2013534 (2020).","journal-title":"The Lancet Infect. Dis."},{"key":"1677_CR2","doi-asserted-by":"publisher","unstructured":"Palacios, R. et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study. SSRN https:\/\/doi.org\/10.2139\/ssrn.3822780 (2021).","DOI":"10.2139\/ssrn.3822780"},{"key":"1677_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","volume":"399","author":"SA Halperin","year":"2022","unstructured":"Halperin, S. A. et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet 399, 237\u2013248 (2022).","journal-title":"Lancet"},{"key":"1677_CR4","unstructured":"Xinhua. Over 1.8 bln doses of COVID-19 vaccines administered in China. Xinhua. http:\/\/www.xinhuanet.com\/english\/2021-08\/11\/c_1310121275.htm (4 August 2021)."},{"key":"1677_CR5","unstructured":"VIPER Group COVID19 Vaccine Tracker Team. COVID19 Vaccine Tracker. https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/ (2021)."},{"key":"1677_CR6","doi-asserted-by":"crossref","unstructured":"Lim, W. W., Mak, L., Leung, G. M., Cowling, B. J. & Peiris, M. Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe 2, e423 (2021).","DOI":"10.1016\/S2666-5247(21)00177-4"},{"key":"1677_CR7","doi-asserted-by":"publisher","unstructured":"Zeng, G. et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/s1473-3099(21)00681-2 (2021).","DOI":"10.1016\/s1473-3099(21)00681-2"},{"key":"1677_CR8","doi-asserted-by":"publisher","unstructured":"Zhu, F. et al. Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime\u2013boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciab845 (2021).","DOI":"10.1093\/cid\/ciab845"},{"key":"1677_CR9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/14760584.2019.1640117","volume":"18","author":"JL Excler","year":"2019","unstructured":"Excler, J. L. & Kim, J. H. Novel prime\u2013boost vaccine strategies against HIV-1. Expert Rev. Vaccines 18, 765\u2013779 (2019).","journal-title":"Expert Rev. Vaccines"},{"key":"1677_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/22221751.2021.1902245","volume":"10","author":"Q He","year":"2021","unstructured":"He, Q. et al. Heterologous prime\u2013boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg. Microbes Infect. 10, 629\u2013637 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"1677_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","volume":"396","author":"FC Zhu","year":"2020","unstructured":"Zhu, F. C. et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396, 479\u2013488 (2020).","journal-title":"Lancet"},{"key":"1677_CR12","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","volume":"397","author":"PA Kristiansen","year":"2021","unstructured":"Kristiansen, P. A. et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet 397, 1347\u20131348 (2021).","journal-title":"Lancet"},{"key":"1677_CR13","doi-asserted-by":"publisher","unstructured":"Atmar, R. L. et al. Heterologous SARS-CoV-2 booster vaccinations\u2014preliminary report. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.10.10.21264827 (2021).","DOI":"10.1101\/2021.10.10.21264827"},{"key":"1677_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","volume":"21","author":"S Lu","year":"2009","unstructured":"Lu, S. Heterologous prime\u2013boost vaccination. Curr. Opin. Immunol. 21, 346\u2013351 (2009).","journal-title":"Curr. Opin. Immunol."},{"key":"1677_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","volume":"34","author":"K Kardani","year":"2016","unstructured":"Kardani, K., Bolhassani, A. & Shahbazi, S. Prime\u2013boost vaccine strategy against viral infections: mechanisms and benefits. Vaccine 34, 413\u2013423 (2016).","journal-title":"Vaccine"},{"key":"1677_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0167-5699(00)01612-1","volume":"21","author":"IA Ramshaw","year":"2000","unstructured":"Ramshaw, I. A. & Ramsay, A. J. The prime\u2013boost strategy: exciting prospects for improved vaccination. Immunol. Today 21, 163\u2013165 (2000).","journal-title":"Immunol. Today"},{"key":"1677_CR17","doi-asserted-by":"crossref","unstructured":"Victora, P. C. et al. Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: analyses of routinely-collected data on vaccine coverage and mortality. EClinicalMedicine 38, 101036 (2021).","DOI":"10.1016\/j.eclinm.2021.101036"},{"key":"1677_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","volume":"398","author":"MD Tanriover","year":"2021","unstructured":"Tanriover, M. D. et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 398, 213\u2013222 (2021).","journal-title":"Lancet"},{"key":"1677_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2107715","volume":"385","author":"A Jara","year":"2021","unstructured":"Jara, A. et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N. Engl. J. Med. 385, 875\u2013884 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1677_CR20","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/s41591-021-01560-x","volume":"27","author":"JA Juno","year":"2021","unstructured":"Juno, J. A. & Wheatley, A. K. Boosting immunity to COVID-19 vaccines. Nat. Med. 27, 1874\u20131875 (2021).","journal-title":"Nat. Med."},{"key":"1677_CR21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.immuni.2010.10.008","volume":"33","author":"F Sallusto","year":"2010","unstructured":"Sallusto, F., Lanzavecchia, A., Araki, K. & Ahmed, R. From vaccines to memory and back. Immunity 33, 451\u2013463 (2010).","journal-title":"Immunity"},{"key":"1677_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"DY Logunov","year":"2020","unstructured":"Logunov, D. Y. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime\u2013boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet 396, 887\u2013897 (2020).","journal-title":"Lancet"},{"key":"1677_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime\u2013boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397, 671\u2013681 (2021).","journal-title":"Lancet"},{"key":"1677_CR24","doi-asserted-by":"crossref","unstructured":"Liu, X. et al. Safety and immunogenicity of heterologous versus homologous prime\u2013boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 398, 856\u2013869 (2021).","DOI":"10.1016\/S0140-6736(21)01694-9"},{"key":"1677_CR25","doi-asserted-by":"publisher","unstructured":"Hillus, D. et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime\u2013boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.05.19.21257334 (2021).","DOI":"10.1101\/2021.05.19.21257334"},{"key":"1677_CR26","doi-asserted-by":"crossref","unstructured":"Normark, J. et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N. Engl. J. Med. 385, 1049\u20131051 (2021).","DOI":"10.1056\/NEJMc2110716"},{"key":"1677_CR27","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/S0140-6736(21)01115-6","volume":"397","author":"RH Shaw","year":"2021","unstructured":"Shaw, R. H. et al. Heterologous prime\u2013boost COVID-19 vaccination: initial reactogenicity data. Lancet 397, 2043\u20132046 (2021).","journal-title":"Lancet"},{"key":"1677_CR28","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S2213-2600(21)00220-4","volume":"9","author":"Y Lustig","year":"2021","unstructured":"Lustig, Y. et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir. Med. 9, 999\u20131009 (2021).","journal-title":"Lancet Respir. Med."},{"key":"1677_CR29","doi-asserted-by":"crossref","unstructured":"Nauta, J. Statistics in Clinical Vaccine Trials (Springer, 2011).","DOI":"10.1007\/978-3-642-14691-6"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01677-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01677-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01677-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T12:42:34Z","timestamp":1645533754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01677-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1677"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01677-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"17 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.W., J.W., J.L. and T.Z. are employees of CanSino Biologics. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}